---
document_datetime: 2025-12-02 04:53:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tenkasi.html
document_name: tenkasi.html
version: success
processing_time: 0.1178027
conversion_datetime: 2025-12-26 20:22:42.041062
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tenkasi (previously Orbactiv)

[RSS](/en/individual-human-medicine.xml/66758)

##### Authorised

This medicine is authorised for use in the European Union

oritavancin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tenkasi (previously Orbactiv)](#news-on)
- [More information on Tenkasi (previously Orbactiv)](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Tenkasi is an antibiotic used in adults and children from 3 months of age to treat acute (short-term) bacterial infections of the skin and of skin structures (tissue below the skin) such as cellulitis (inflammation of the deep skin tissue), skin abscesses and wound infections. It contains the active substance oritavancin.

Expand section

Collapse section

## How is Tenkasi used?

Tenkasi is given as a single infusion (drip) into a vein. The medicine can only be obtained with a prescription. Before using Tenkasi, doctors should consider official guidance on the appropriate use of antibiotics.

For more information about using Tenkasi, see the package leaflet or contact your healthcare provider.

## How does Tenkasi work?

The active substance in Tenkasi, oritavancin, is a type of antibiotic called a glycopeptide. It works by preventing certain bacteria from making their own cell walls, thereby killing the bacteria. Tenkasi has been shown to work against bacteria (such as methicillin resistant Staphylococcus aureus (MRSA)) for which standard antibiotics do not work.

## What benefits of Tenkasi have been shown in studies?

Tenkasi, given as a single infusion, was compared with a 7- to 10-day treatment with vancomycin (another glycopeptide) in two main studies involving a total of around 1,959 patients with acute bacterial infections of the skin and of skin structures, such as cellulitis, skin abscesses and wound infections. These also included infections caused by MRSA.

In both studies, the main measure of effectiveness was the number of patients who responded within 3 days of starting treatment with an improvement in their skin in the infected area, lack of fever and no need for additional antibiotic. The study also looked at the number of patients whose infection was cured after treatment.

Tenkasi was at least as effective as vancomycin at treating the infection: 80.1% of patients treated with Tenkasi in the first study and 82.3% in the second study responded to treatment, compared with 82.9% and 78.9% respectively of patients treated with vancomycin. In addition, 82.7% of patients treated with Tenkasi in the first study and 79.6% in the second study were cured, compared with 80.5% and 80.0% respectively of patients treated with vancomycin.

An additional study involving 38 children from 3 months to less than 18 years of age showed that when given at the recommended dose in children of this age range, Tenkasi led to blood levels of the active substance, oritavancin, similar to those seen in adults.

## What are the risks associated with Tenkasi?

For the full list of side effects and restrictions with Tenkasi, see the package leaflet.

The most common side effects with Tenkasi (which may affect 5 people or more in 100) are nausea (feeling sick), hypersensitivity (allergy) reactions or reactions at the site of infusion and headache. The most common side effects that resulted in treatment being stopped were cellulitis and osteomyelitis (bone infection).

Patients who have received Tenkasi must not be given an infusion of unfractionated heparin (a medicine used to prevent blood clots) for 120 hours after the infusion of Tenkasi. For the full list of side effects and restrictions with Tenkasi, see the package leaflet.

## Why is Tenkasi approved?

The European Medicines Agency noted that Tenkasi, which can be given as a single dose, could be a valuable alternative treatment option for acute bacterial infections of the skin and of skin structures.

Tenkasi's safety profile overall is similar to that of other glycopeptides, although some side effects occurred more frequently such as abscesses and bone infections. EMA considered that these side effects were manageable and adequately addressed in the product information.

The European Medicines Agency concluded that Tenkasi's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Tenkasi?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tenkasi have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tenkasi are continuously monitored. Suspected side effects reported with Tenkasi are carefully evaluated and any necessary action taken to protect patients.

## Other information about Tenkasi

Orbactiv received a marketing authorisation valid throughout the EU on 19 March 2015. The name of the medicine was changed to Tenkasi on 09 August 2021.

Tenkasi : EPAR - Medicine overview

Reference Number: EMA/167280/2023

English (EN) (148.5 KB - PDF)

**First published:** 04/05/2015

**Last updated:** 24/05/2023

[View](/en/documents/overview/tenkasi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-898)

български (BG) (221.33 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/bg/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_bg.pdf)

español (ES) (175.04 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/es/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_es.pdf)

čeština (CS) (200.19 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/cs/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_cs.pdf)

dansk (DA) (175.78 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/da/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_da.pdf)

Deutsch (DE) (177.4 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/de/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_de.pdf)

eesti keel (ET) (170.62 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/et/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_et.pdf)

ελληνικά (EL) (217.83 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/el/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_el.pdf)

français (FR) (150.25 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/fr/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_fr.pdf)

hrvatski (HR) (153.21 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/hr/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_hr.pdf)

italiano (IT) (175.99 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/it/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (215.25 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/lv/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (198.34 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/lt/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_lt.pdf)

magyar (HU) (196.21 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/hu/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_hu.pdf)

Malti (MT) (226.63 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/mt/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_mt.pdf)

Nederlands (NL) (176.13 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/nl/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_nl.pdf)

polski (PL) (200.59 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/pl/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_pl.pdf)

português (PT) (176.89 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/pt/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_pt.pdf)

română (RO) (205.06 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/ro/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_ro.pdf)

slovenčina (SK) (199.16 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/sk/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_sk.pdf)

slovenščina (SL) (196.78 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/sl/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_sl.pdf)

Suomi (FI) (171.63 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/fi/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_fi.pdf)

svenska (SV) (173.35 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

24/05/2023

[View](/sv/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_sv.pdf)

Tenkasi : EPAR - Risk-management-plan summary

English (EN) (48.59 KB - PDF)

**First published:** 04/05/2015

**Last updated:** 22/09/2023

[View](/en/documents/rmp-summary/tenkasi-epar-risk-management-plan-summary_en.pdf)

## Product information

Tenkasi : EPAR - Product Information

English (EN) (461.54 KB - PDF)

**First published:** 04/05/2015

**Last updated:** 20/11/2024

[View](/en/documents/product-information/tenkasi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-720)

български (BG) (671.06 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/bg/documents/product-information/tenkasi-epar-product-information_bg.pdf)

español (ES) (544.58 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/es/documents/product-information/tenkasi-epar-product-information_es.pdf)

čeština (CS) (536.88 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/cs/documents/product-information/tenkasi-epar-product-information_cs.pdf)

dansk (DA) (311.45 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/da/documents/product-information/tenkasi-epar-product-information_da.pdf)

Deutsch (DE) (415.56 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/de/documents/product-information/tenkasi-epar-product-information_de.pdf)

eesti keel (ET) (589.89 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/et/documents/product-information/tenkasi-epar-product-information_et.pdf)

ελληνικά (EL) (745.41 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/el/documents/product-information/tenkasi-epar-product-information_el.pdf)

français (FR) (610.19 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/fr/documents/product-information/tenkasi-epar-product-information_fr.pdf)

hrvatski (HR) (504.9 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/hr/documents/product-information/tenkasi-epar-product-information_hr.pdf)

íslenska (IS) (298.03 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/is/documents/product-information/tenkasi-epar-product-information_is.pdf)

italiano (IT) (403.87 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/it/documents/product-information/tenkasi-epar-product-information_it.pdf)

latviešu valoda (LV) (421.08 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/lv/documents/product-information/tenkasi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (385.37 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/lt/documents/product-information/tenkasi-epar-product-information_lt.pdf)

magyar (HU) (513.18 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/hu/documents/product-information/tenkasi-epar-product-information_hu.pdf)

Malti (MT) (493.19 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/mt/documents/product-information/tenkasi-epar-product-information_mt.pdf)

Nederlands (NL) (462.17 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/nl/documents/product-information/tenkasi-epar-product-information_nl.pdf)

norsk (NO) (229.08 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/no/documents/product-information/tenkasi-epar-product-information_no.pdf)

polski (PL) (584.29 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/pl/documents/product-information/tenkasi-epar-product-information_pl.pdf)

português (PT) (352.25 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/pt/documents/product-information/tenkasi-epar-product-information_pt.pdf)

română (RO) (545.05 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/ro/documents/product-information/tenkasi-epar-product-information_ro.pdf)

slovenčina (SK) (591.74 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/sk/documents/product-information/tenkasi-epar-product-information_sk.pdf)

slovenščina (SL) (588.07 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/sl/documents/product-information/tenkasi-epar-product-information_sl.pdf)

Suomi (FI) (337.07 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/fi/documents/product-information/tenkasi-epar-product-information_fi.pdf)

svenska (SV) (340.07 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

20/11/2024

[View](/sv/documents/product-information/tenkasi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IA/0046 19/11/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tenkasi : EPAR - All Authorised presentations

English (EN) (16.2 KB - PDF)

**First published:** 04/05/2015

**Last updated:** 22/09/2023

[View](/en/documents/all-authorised-presentations/tenkasi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-794)

български (BG) (62.86 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/bg/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_bg.pdf)

español (ES) (44.36 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/es/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_es.pdf)

čeština (CS) (62.25 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/cs/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (30.52 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/da/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (23.16 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/de/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (7.45 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/et/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (42.72 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/el/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_el.pdf)

français (FR) (19.28 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/fr/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (78.36 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/hr/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (30.39 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/is/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_is.pdf)

italiano (IT) (13.07 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/it/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (30.01 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/lv/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (20.67 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/lt/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (26.26 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/hu/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (37.1 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/mt/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (10.67 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/nl/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (7.35 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/no/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_no.pdf)

polski (PL) (46.42 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/pl/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_pl.pdf)

português (PT) (7.45 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/pt/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_pt.pdf)

română (RO) (60.93 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/ro/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (46.77 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/sk/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (46.54 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/sl/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (8.25 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/fi/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (7.48 KB - PDF)

**First published:**

04/05/2015

**Last updated:**

22/09/2023

[View](/sv/documents/all-authorised-presentations/tenkasi-previously-orbactiv-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tenkasi (previously Orbactiv) Active substance oritavancin (diphosphate) International non-proprietary name (INN) or common name oritavancin Therapeutic area (MeSH)

- Soft Tissue Infections
- Skin Diseases, Bacterial

Anatomical therapeutic chemical (ATC) code J01XA05

### Pharmacotherapeutic group

Antibacterials for systemic use

### Therapeutic indication

Tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients aged 3 months and older (see sections 4.2, 4.4 and 5.1).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

## Authorisation details

EMA product number EMEA/H/C/003785 Marketing authorisation holder

Menarini International Operations Luxembourg S.A.

1, Avenue de la Gare

Marketing authorisation issued 19/03/2015 Revision 16

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tenkasi: EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (150.58 KB - PDF)

**First published:** 31/03/2016

**Last updated:** 20/11/2024

[View](/en/documents/procedural-steps-after/tenkasi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tenkasi-H-C-003785-X-0036 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/323178/2023

English (EN) (1010.87 KB - PDF)

**First published:** 22/09/2023

[View](/en/documents/variation-report/tenkasi-h-c-003785-x-0036-epar-assessment-report-variation_en.pdf)

Tenkasi-H-C-003785-II-0037 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/783414/2023

English (EN) (1.57 MB - PDF)

**First published:** 08/06/2023

[View](/en/documents/variation-report/tenkasi-h-c-003785-ii-0037-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Tenkasi (II-37)

Adopted

Reference Number: EMA/CHMP/150406/2023

English (EN) (127.23 KB - PDF)

**First published:** 31/03/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tenkasi-ii-37_en.pdf)

Tenkasi-H-C-PSUSA-00010368-202003 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/691672/2020

English (EN) (191.23 KB - PDF)

**First published:** 18/12/2020

[View](/en/documents/scientific-conclusion/tenkasi-h-c-psusa-00010368-202003-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Tenkasi-H-C-PSUSA-00010368-201903 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/38415/2020

English (EN) (127.98 KB - PDF)

**First published:** 23/01/2020

[View](/en/documents/scientific-conclusion/tenkasi-h-c-psusa-00010368-201903-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Tenkasi-H-C-PSUSA-00010368-201709 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/443903/2018

English (EN) (68.75 KB - PDF)

**First published:** 04/07/2018

**Last updated:** 04/07/2018

[View](/en/documents/scientific-conclusion/tenkasi-h-c-psusa-00010368-201709-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

## Initial marketing authorisation documents

Tenkasi: EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/803704/2015

English (EN) (3.95 MB - PDF)

**First published:** 04/05/2015

**Last updated:** 04/05/2015

[View](/en/documents/assessment-report/tenkasi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Orbactiv

Adopted

Reference Number: EMA/CHMP/803701/2014

English (EN) (88.07 KB - PDF)

**First published:** 23/01/2015

**Last updated:** 29/01/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-orbactiv_en.pdf)

#### News on Tenkasi (previously Orbactiv)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-march-2023) 31/03/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 January 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-january-2015) 23/01/2015

#### More information on Tenkasi (previously Orbactiv)

- [EMEA-001270-PIP01-12-M07 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001270-pip01-12-m07)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 20/11/2024

## Share this page

[Back to top](#main-content)